CoChat

Pioglitazone could induce remission in major depression: a meta-analysis

Open access
Colle, Romain, de Larminat, Delphine, Rotenberg, Samuel, Hozer, Franz, Hardy, Patrick, Verstuyft, Céline, Fève, Bruno, Corruble, Emmanuelle · 2016 · Neuropsychiatric Disease and Treatment
Cited by 73

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Background: Pioglitazone, a selective agonist of the nuclear transcription factor peroxisome proliferator-activated receptor-gamma (PPAR-γ), prescribed for the treatment of type 2 diabetes, could have antidepressant properties. However, its potential to induce remission of major depressive episodes, the optimal clinical target for an antidepressant drug, is a matter of concern. Indeed, only one out of four double-blind randomized controlled trials show higher remission rates with pioglitazone than with control treatments. Hence, the main aim of this study was to perform a meta-analysis of the efficacy of pioglitazone for the treatment of MDE, focusing on remission rates. Methods: Four double-blind randomized controlled trials, comprising 161 patients with an MDE, were included in this meta-analysis. Pioglitazone was studied either alone (one study) or as add-on therapy to conventional treatments (antidepressant drugs or lithium salts). It was compared either to placebo (three studies) or to metformin (one study). Remission was defined by a Hamilton Depression Rating Scale score <8 after treatment. Results: Pioglitazone could induce higher remission rates than control treatments (27% versus 10%, I 2 =17.3%, fixed-effect model: odds ratio [OR] =3.3, 95% confidence interval [95% CI; 1.4; 7.8], P =0.008). The OR was even higher in the subgroup of patients with major depressive disorder (n=80; 23% versus 8%, I 2 =0.0%; fixed-effect model: OR =5.9, 95% CI [1.6; 22.4], P =0.009) and in the subgroup of patients without metabolic comorbidities (n=84; 33% versus 10%, I 2 =0.0%; fixed-effect model: OR =5.1, 95% CI [1.5; 17.9], P =0.01). As compared to control treatments, results suggest six patients would need to be treated with pioglitazone in order to achieve the possibility of one more remission. Conclusion: Pioglitazone, either alone or as add-on therapy to conventional treatments, could induce remission of MDE, suggesting that drugs with PPAR-γ agonist properties may be true and clinically relevant antidepressants, even in patients without metabolic comorbidities. Keywords: pioglitazone, major depressive episode, major depressive disorder, bipolar disorder, remission, meta-analysis

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ndt.s121149

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 73

Metadata

Authors
Colle, R., de Larminat, D., Rotenberg, S., Hozer, F., Hardy, P., Verstuyft, C., Fève, B., & Corruble, E.
Venue
Neuropsychiatric Disease and Treatment
Published
2016-12
Volume
Volume 13
Pages
9-16
ISSN
  • 1176-6328 (ISSN-L)
  • 1178-2021
OpenAlex
W2564398793
Cited by
73
References
15
FWCI
1.93
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pioglitazone could induce remission in major depression: a meta-analysis. https://app.cochat.ai/papers/10.2147/ndt.s121149
The paper
Colle, R., de Larminat, D., Rotenberg, S., Hozer, F., Hardy, P., Verstuyft, C., Fève, B., & Corruble, E. (2016). Pioglitazone could induce remission in major depression: a meta-analysis. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s121149

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.